Medpace Holdings, Inc. MEDP Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | 21%-0.1pp | 21.1%0.0pp | 21.5%+1.8pp | 21.4%+2.6pp | 21.2%+3.1pp | |
| Net margin | 17.2%-2.1pp | 17.8%-1.3pp | 18.4%+0.7pp | 18.7%+2.0pp | 19.3%+3.4pp | |
| EBITDA margin | 22.1%-0.4pp | 22.3%-0.3pp | 22.7%+1.6pp | 22.7%+2.5pp | 22.5%+3.0pp | |
| Free cash flow margin | 26.5%+1.5pp | 26.9%-0.2pp | 28.7%+2.8pp | 26%+1.2pp | 25.1%+1.0pp | |
| Returns | ||||||
| Return on equity | 77.3%+11.4pp | 70.2%+11.8pp | 73.7%+19.6pp | 89.4%+30.5pp | 65.8%+4.5pp | |
| Return on assets | 22.9%+0.3pp | 22.1%+0.6pp | 22.6%+2.1pp | 24%+3.5pp | 22.5%+3.0pp | |
| Return on invested capital | 229.9%+121pp | 220%+123pp | 159.9%+84.4pp | 118.2%+51.1pp | 108.9%+47.7pp | |
| Efficiency | ||||||
| Asset turnover | 1.3×+0.2× | 1.2×+0.1× | 1.2×+0.1× | 1.3×+0.1× | 1.2×-0.1× | |
| Liquidity | ||||||
| Current ratio | 0.8×+0.1× | 0.7×-0.2× | 0.6×-0.4× | 0.4×-0.5× | 0.7×0.0× | |
| Quick ratio | 0.8×+0.1× | 0.7×-0.2× | 0.6×-0.4× | 0.4×-0.5× | 0.7×0.0× | |
| Cash ratio | 0.5×+0.1× | 0.4×-0.2× | 0.2×-0.4× | 0×-0.5× | 0.4×0.0× | |
| Leverage | ||||||
| Debt-to-equity | 0.2×0.0× | 0.3×+0.1× | 0.5×+0.3× | 0.9×+0.7× | 0.3×0.0× | |
| Debt-to-assets | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Net debt / EBITDA | -0.9×-0.3× | -0.6×+0.5× | -0.3×+0.9× | 0.2×+1.1× | -0.6×+0.1× | |
| Interest coverage | 49.2×— | 41.9×— | 29.9×— | —— | —— | |
| Per Share | ||||||
| Book value per share | $20.66+8.6% | $15.55-39.7% | $10.19-62.9% | $5.91-75.1% | $19.03-9.3% | |
| Valuation | ||||||
| Market capitalization | $13.63B+46.8% | $15.82B+53.2% | $14.44B+39.6% | $9.06B-28.7% | $9.28B-25.5% | |
| Enterprise value | $13.12B+45.9% | $15.46B+57.7% | $14.3B+45.4% | $9.17B-25.8% | $8.99B-26.4% | |
| Price / earnings | 29.6×+7.3× | 35.1×+9.5× | 33.4×+5.1× | 21.7×-15.7× | 22.3×-17.6× | |
| Price / sales | 5.1×+0.8× | 6.3×+1.4× | 6.1×+1.1× | 4.1×-2.2× | 4.3×-2.0× | |
| Price / book | 22.8×+7.1× | 34.5×+22.0× | 49.2×+37.5× | 52.6×+35.9× | 15.6×-2.9× | |
| EV / EBITDA | 22.2×+3.7× | 27.5×+6.9× | 26.7×+4.2× | 18.1×-12.1× | 18.5×-13.5× | |
| EV / sales | 4.9×+0.7× | 6.1×+1.5× | 6.1×+1.3× | 4.1×-2.0× | 4.2×-2.1× | |
| Free cash flow yield | 5.2%-0.6pp | 4.3%-1.2pp | 4.7%-0.5pp | 6.4%+2.4pp | 5.8%+2.0pp | |
| Earnings yield | 3.4%-1.1pp | 2.9%-1.1pp | 3%-0.5pp | 4.6%+1.9pp | 4.5%+2.0pp | |
| PEG ratio | 2.8×+2.1× | 3×+2.4× | 1.8×+1.0× | 0.9×-0.5× | 0.7×-1.2× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Medpace Holdings, Inc.'s ratios come from?
- Every ratio is computed from Medpace Holdings, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
